Market Overview

UPDATE: Jefferies Raises PT on Infinity Pharmaceuticals on IPI-145 Sales Potential

Related INFI
Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma
3 Partnerships Pushing The Pharmaceutical Sector Forward

In a report published Wednesday, Jefferies reiterated its Hold rating on Infinity Pharmaceuticals (NASDAQ: INFI), and raised its price target from $21.00 to $41.00.

Jefferies noted, “Wider 4Q12 loss of ~$47M (vs. our loss estimate of ~$29M); cash of $327M at YE12 sufficient into ~2015. With expanding cohorts in Ph1/2a, timing for Ph3 start is likely in ~2014. INFI's rising valuation implies IPI-145 sales potential at >~$3B; however, given evolving competitive field with several promising products well ahead of IPI-145, speedy, comprehensive development strategy is key to realizing its commercial potential.”

Infinity Pharmaceuticals closed on Tuesday at $45.14.

Latest Ratings for INFI

DateFirmActionFromTo
Oct 2014Stifel NicolausInitiates Coverage onHold
Sep 2014JMP SecuritiesUpgradesMarket PerformMarket Outperform
Sep 2014JefferiesMaintainsBuy

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (INFI)

Around the Web, We're Loving...

Get Benzinga's Newsletters